Table 4.
Comparing our results with other studies
| Study | n | Duration of TKI, m | Clinical stage, n (%) | Surgery, n (%) | Post operative complications, n | Adjuvant TKI, Y/N/U | PFS/OS, m |
|---|---|---|---|---|---|---|---|
| Ohtaki et al. [23] | 36 | 14 |
IIIA, 8 (22.2) IIIB, 4 (11.1) IV, 21 (58.3) R, 3 (8.3) |
Lobectomy, 28 (77.8) Segmentectomy, 3 (8.3) Wedge resection, 2 (5.6) Bilobectomy, 1 (2.8) Pneumonectomy, 2 (5.6) |
Bleeding, 1 Empyema, 1 |
16/20/0 | 15/58 |
| Song et al. [24] | 9 | 6 (2–46) |
IIIA, 2 (22.2) IIIB, 1 (11.1) IV, 6 (66.7) |
Lobectomy, 9 (100%) | Atrial fibrillation, 1 | 9/0/0 | 14/17 |
| Yamamoto et al. [25] | 24 | 3 (0.7–36) |
IB, 1 (4.2) IIIA, 8 (33.3) IIIB, 5 (20.8) IV, 10 (41.7) |
Lobectomy, 15 (62.5) Bilobectomy, 5 (20.8) Pneumonectomy, 4 (16.7) |
Empyema, 1 Chylothorax, 1 |
12/9/3 | 10/68 |
| Ning et al. [26] | 10 | 3 (3–5) |
IIIA, 2 (20) IIIB, 8 (80) |
Lobectomy, 9 (90) Pneumonectomy, 1 (10) |
Death, 1 | 9/0/0 | 14/36 |
CR complete response, TKI tyrosine kinase inhibitor, PFS progression-free survival, OS overall survival, R recurrent, U unknown, m month, Y yes, N No